Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Gyre Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -33.9%. For fiscal 2025 it was 8.5%, against 16.9% the year before. The highest annual figure on record is 16.9% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.5% | −8.4 |
| FY2024 | Dec 31, 2024 | 16.9% | +92.3 |
| FY2023 | Dec 31, 2023 | -75.3% | −79.6 |
| FY2022 | Dec 31, 2022 | 4.2% | +1202.5 |
| FY2021 | Dec 31, 2021 | -1198.3% | −929.8 |
| FY2020 | Dec 31, 2020 | -268.5% | +500648.2 |
| FY2018 | Dec 31, 2018 | -500916.7% | −498798.7 |
| FY2017 | Dec 31, 2017 | -2118.0% | +286.8 |
| FY2014 | Dec 31, 2014 | -2404.7% | −2130.1 |
| FY2013 | Dec 31, 2013 | -274.6% | −262.5 |
| FY2012 | Dec 31, 2012 | -12.1% | −3.4 |
| FY2011 | Dec 31, 2011 | -8.7% | −21.5 |
| FY2010 | Dec 31, 2010 | 12.7% | +169.9 |
| FY2009 | Dec 31, 2009 | -157.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -7.5% | −13.4 |
| Q2 FY2026 | Jun 30, 2026 | -49.0% | −41.5 |
| Q1 FY2026 | Mar 31, 2026 | -82.5% | −104.9 |
| Q4 FY2025 | Dec 31, 2025 | -5.6% | −7.7 |
| Q3 FY2025 | Sep 30, 2025 | 5.9% | −5.3 |
| Q2 FY2025 | Jun 30, 2025 | -7.5% | −25.5 |
| Q1 FY2025 | Mar 31, 2025 | 22.4% | −14.2 |
| Q4 FY2024 | Dec 31, 2024 | 2.1% | +303.1 |
| Q3 FY2024 | Sep 30, 2024 | 11.2% | −12.2 |
| Q2 FY2024 | Jun 30, 2024 | 18.0% | +5.1 |
| Q1 FY2024 | Mar 31, 2024 | 36.6% | +19.6 |
| Q4 FY2023 | Dec 31, 2023 | -300.9% | +1529.8 |
| Q3 FY2023 | Sep 30, 2023 | 23.4% | +856.6 |
| Q2 FY2023 | Jun 30, 2023 | 12.9% | +1110.6 |
| Q1 FY2023 | Mar 31, 2023 | 16.9% | +1777.3 |
| Q1 FY2022 | Mar 31, 2022 | -1830.7% | −301.2 |
| Q4 FY2021 | Dec 31, 2021 | -833.2% | +97.8 |
| Q3 FY2021 | Sep 30, 2021 | -1097.8% | +697.6 |
| Q2 FY2021 | Jun 30, 2021 | -1760.4% | −720.1 |
| Q1 FY2021 | Mar 31, 2021 | -1529.5% | −1504.8 |
| Q4 FY2020 | Dec 31, 2020 | -930.9% | +83102.4 |
| Q3 FY2020 | Sep 30, 2020 | -1795.4% | +13.7 |
| Q2 FY2020 | Jun 30, 2020 | -1040.3% | +781.4 |
| Q1 FY2020 | Mar 31, 2020 | -24.8% | +5269.8 |
| Q1 FY2018 | Mar 31, 2018 | -84033.3% | – |
| Q4 FY2017 | Dec 31, 2017 | -1809.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -1821.7% | – |
| Q2 FY2017 | Jun 30, 2017 | -5294.6% | – |
See a number that looks wrong?